Literature DB >> 2070579

Paradoxical lack of ultrasound attenuation with gross fatty change in the liver.

R J Davies1, S H Saverymuttu, M Fallowfield, A E Joseph.   

Abstract

The cardinal features of hepatic steatosis on ultrasound examination are now accepted as increased echogenicity of the liver parenchyma with increased attenuation of the ultrasound beam. Three cases are presented of patients with gross diffuse fatty infiltration of the liver, who showed a paradoxical lack of posterior attenuation on ultrasound examination. These examples serve to illustrate the role of scattering in attenuation of the ultrasound beam seen in fatty livers.

Entities:  

Mesh:

Year:  1991        PMID: 2070579     DOI: 10.1016/s0009-9260(05)80567-7

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  5 in total

1.  Fatty infiltration of liver in hyperlipidemic patients.

Authors:  N Assy; K Kaita; D Mymin; C Levy; B Rosser; G Minuk
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

2.  Prevalence of liver steatosis and fibrosis and the diagnostic accuracy of ultrasound in bariatric surgery patients.

Authors:  Jiang Wu; Jing You; Lisa Yerian; Ayako Shiba; Philip R Schauer; Daniel I Sessler
Journal:  Obes Surg       Date:  2012-02       Impact factor: 4.129

Review 3.  Managing nonalcoholic fatty liver disease: recommendations for family physicians.

Authors:  Ignazio Grattagliano; Piero Portincasa; Vincenzo O Palmieri; Giuseppe Palasciano
Journal:  Can Fam Physician       Date:  2007-05       Impact factor: 3.275

4.  Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study.

Authors:  Srinivasan Dasarathy; Jaividhya Dasarathy; Amer Khiyami; Rajesh Joseph; Rocio Lopez; Arthur J McCullough
Journal:  J Hepatol       Date:  2009-09-20       Impact factor: 25.083

5.  A case-control study of non-alcoholic fatty liver disease in breast cancer.

Authors:  Ahmet Bilici; Mustafa Ozguroglu; Ismail Mihmanli; Hande Turna; Ibrahim Adaletli
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.